Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) — Market Cap & Net Worth
Market Cap & Net Worth: Kiniksa Pharmaceuticals Ltd (KNSA)
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) has a market capitalization of $2.42 Billion ($2.42 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5696 globally and #1804 in its home market, demonstrating a 6.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kiniksa Pharmaceuticals Ltd's stock price $52.30 by its total outstanding shares 46303276 (46.30 Million). Review Kiniksa Pharmaceuticals Ltd (KNSA) total liabilities to assess the company's total debt and financial obligations.
Kiniksa Pharmaceuticals Ltd Market Cap History: 2018 to 2026
Kiniksa Pharmaceuticals Ltd's market capitalization history from 2018 to 2026. Data shows growth from $1.30 Billion to $2.42 Billion (13.03% CAGR).
Index Memberships
Kiniksa Pharmaceuticals Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.10% | #137 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.01% | #627 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.14% | #90 of 263 |
Weight: Kiniksa Pharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kiniksa Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kiniksa Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.82x
Kiniksa Pharmaceuticals Ltd's market cap is 2.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
32.37x
Kiniksa Pharmaceuticals Ltd's market cap is 32.37 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $818.18 Million | $7.70 Million | -$161.38 Million | 106.20x | N/A |
| 2021 | $544.99 Million | $38.54 Million | -$157.92 Million | 14.14x | N/A |
| 2022 | $693.62 Million | $220.18 Million | $183.36 Million | 3.15x | 3.78x |
| 2023 | $812.16 Million | $270.26 Million | $14.08 Million | 3.01x | 57.67x |
| 2024 | $915.88 Million | $423.24 Million | -$43.19 Million | 2.16x | N/A |
| 2025 | $1.91 Billion | $677.56 Million | $59.01 Million | 2.82x | 32.37x |
Competitor Companies of KNSA by Market Capitalization
Companies near Kiniksa Pharmaceuticals Ltd in the global market cap rankings as of June 17, 2026.
Key companies related to Kiniksa Pharmaceuticals Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Kiniksa Pharmaceuticals Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Kiniksa Pharmaceuticals Ltd's market cap moved from $1.30 Billion to $ 2.42 Billion, with a yearly change of 13.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.42 Billion | +26.79% |
| 2025 | $1.91 Billion | +108.54% |
| 2024 | $915.88 Million | +12.77% |
| 2023 | $812.16 Million | +17.09% |
| 2022 | $693.62 Million | +27.27% |
| 2021 | $544.99 Million | -33.39% |
| 2020 | $818.18 Million | +59.76% |
| 2019 | $512.11 Million | -60.63% |
| 2018 | $1.30 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Kiniksa Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.42 Billion USD |
| MoneyControl | $2.42 Billion USD |
| MarketWatch | $2.42 Billion USD |
| marketcap.company | $2.42 Billion USD |
| Reuters | $2.42 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-3… Read more